Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
87,994
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,567.00 | 12.10 | -0.14% |
CAC 40 | 7,213.32 | 14.87 | 0.21% |
DAX 40 | 19,146.17 | 141.39 | 0.74% |
Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
FTSE 100 | 8,149.27 | 64.20 | 0.79% |
HKSE | 19,601.11 | 103.90 | -0.53% |
NASDAQ | 18,972.42 | 6.28 | 0.03% |
Nikkei 225 | 38,026.17 | 326.17 | -0.85% |
NZX 50 Index | 12,811.69 | 46.45 | 0.36% |
S&P 500 | 5,948.71 | 31.60 | 0.53% |
S&P/ASX 200 | 8,323.00 | 3.30 | -0.04% |
SSE Composite Index | 3,370.40 | 2.41 | 0.07% |